ASCOT-LLA: Statin Legacy Felt with Reduced Non-CV Death Eight Years after Trial End?

Abstract

Prior treatment with atorvastatin is associated with a reduction in the risk of all-cause mortality compared with placebo 8 years after the early termination of the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm [ASCOT-LLA] and 11 years after initial randomization, according to new findings from a long-term follow-up study.